IP Library › Granted Patent US 11,771,646
Granted Patent B2
US 11,771,646 · App. 17/062,196 · Granted Oct 3, 2023

Needle assisted jet injection administration of testosterone compositions

Inventors: Paul K. Wotton (Newtown, PA); Kaushik J. Dave (Edison, NJ); John W. Hayes (Chaska, MN); Peter L. Sadowski (Woodbury, MN); Hermanus L. Jooste (Wayne, PA); Jonathan Jaffe (Annandale, NJ)
Assignee: ANTARES PHARMA, INC.
A61K9/0019A61K31/56A61K31/568A61M5/002A61M5/2033A61M5/30A61M5/3153A61M5/3202A61M5/326A61M5/425A61M5/44A61M37/00A61M2005/206A61M2005/2013A61M2005/2073A61M2205/364A61M2205/3613A61M2205/3673
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,771,646
App. No.
17/062,196
Filed
Oct 2, 2020
Granted
Oct 3, 2023
Kind
B2
Art Unit
3783
USPC
604/115
Abstract

The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

Claims (39)

1. An injection device, comprising:

a housing member having a distal end and a proximal end;

a chamber disposed within the housing member configured to hold an amount of a preservative-free medicament comprising testosterone;

a needle operatively associated with the chamber and having a length sufficient to deliver the medicament to an injection site at a depth below a patient's skin sufficient to minimize leak-back;

a plunger movable within the chamber;

a force generating source capable of providing sufficient force on the plunger to eject at least a portion of the medicament from the chamber through the needle in less than about 20 seconds; and

a heating mechanism coupled to the chamber and configured to raise the temperature of the preservative-free medicament comprising testosterone above ambient temperature.

2. The injection device of claim 1 , wherein the injection site is subcutaneous.

3. The injection device of claim 1 , wherein the force on the plunger is configured to eject at least a portion of the medicament from the chamber through the needle in less than about 15 seconds.

4. The injection device of claim 1 , wherein the force on the plunger is configured to eject all of the medicament from the chamber through the needle in less than about 15 seconds.

5. The injection device of claim 1 , wherein the force on the plunger is configured to eject all of the medicament from the chamber through the needle in less than about 10 seconds.

6. The injection device of claim 1 , wherein the needle length is greater than about 5 mm.

7. The injection device of claim 1 , wherein the needle length is less than about 20 mm.

8. The injection device of claim 1 , wherein the needle length is between about 5 mm and 12 mm.

9. The injection device of claim 1 , wherein a gauge of the needle is 27 gauge.

10. The injection device of claim 1 , wherein a gauge of the needle is 25 gauge to 30 gauge.

11. The injection device of claim 1 , wherein the needle has a bore between 0.3 mm to 0.5 mm.

12. The injection device of claim 1 , wherein when used, there is substantially no leak-back.

13. The injection device of claim 1 , wherein when used, there is no leak-back.

14. The injection device of claim 1 , wherein when used, the force generating source generates sufficient force such that there is no leak-back in about 95% of injections.

15. The injection device of claim 1 , wherein when used, the amount of leak back is less than about 15% of the total injected volume of medicament.

16. The injection device of claim 1 , wherein when used, the amount of leak back is no more than the amount of leak back selected from the group consisting of about 0.05% to about 15% of the total injected volume of medicament, about 0.1% to about 12.5% of the total injected volume of medicament, about 0.2% to about 10% of the total injected volume of medicament, about 0.3% to about 7.5% of the total injected volume of medicament, about 0.4% to about 5% of the total injected volume of medicament, about 0.5% to about 3% of the total injected volume of medicament, about 0.6% to about 2% of the total injected volume of medicament, about 0.7% to about 1% of the total injected volume of medicament.

17. The injection device of claim 1 , wherein when used, the amount of leak back is less than about 15% of the total weight of the injected medicament.

18. The injection device of claim 1 , wherein when used, the amount of leak back is no more than the amount of leak back selected from the group consisting of about 0.1% to about 15% of the total weight of the injected medicament, about 0.5% to about 12.5% of the total weight of the injected medicament, about 1% to about 10% of the total weight of the injected medicament, about 2% to about 7.5% of the total weight of the injected medicament, and about 3% to about 5% of the total weight of the injected medicament.

19. The injection device of claim 1 , further comprising a collar surrounding the needle and defining a collar cavity, the collar having a peripheral and forward skin-contacting surface that surrounds, is discontinuous, and is radially spaced from the needle and injection site by an area that is sufficiently large to allow a patient's skin to move into the collar cavity to properly position the needle to penetrate the patient for intradermal delivery of the medicament to the injection site to allow spread of the injected medicament under the skin while inhibiting or preventing backpressure within the skin from forcing the medicament out through the injection site.

20. The injector device of claim 1 , wherein the heating mechanism comprises at least one of an electrical, chemical or exothermic source.

21. The injection device of claim 1 , wherein the heating mechanism is configured to raise the preservative-free medicament comprising testosterone at least 5 degrees C. above ambient temperature.

22. The injection device of claim 1 , wherein the heating mechanism comprises an indicator that the preservative-free medicament comprising testosterone has reached a desired temperature.

23. The injection device of claim 1 , further comprising:

the preservative-free medicament comprising testosterone.

24. An injection device comprising:

a housing;

a cartridge container disposed within the housing;

a cartridge received within the cartridge container, the cartridge having at least one opening therein and containing a medicament comprising testosterone, the medicament rearwardly confined by a plunger, wherein the cartridge includes a needle assembly to dispense the medicament there through, the needle assembly comprising a needle and a non-removable protective needle sheath, the needle having a length sufficient to deliver the medicament to an injection site at a depth below a patient's skin sufficient to minimize leak-back;

an actuation assembly providing a stored energy source capable of being released to drive the needle through the protective needle sheath and to drive the plunger within the cartridge to dispense the medicament through the needle assembly, the stored energy source providing a force sufficient to eject at least a portion of the medicament from the cartridge through the needle in less than about 20 seconds;

a needle cover received within the housing, the needle cover having an opening formed therein to permit the passage of the needle assembly there through during a medicament dispensing operation, the needle cover having a first locked position whereby the needle cover is in a locked retracted position prior to activation of the auto-injector, the needle cover having a second locked position whereby the needle cover is in a locked extended position after operation of the auto-injector;

a first locking assembly that holds the needle cover in the first locked position;

a second locking assembly that holds the needle cover in the second locked position; and

a heating mechanism coupled to the cartridge and configured to raise the temperature of the medicament comprising testosterone above ambient temperature.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2022
From: WOTTON, PAUL K.; DAVE, KAUSHIK J.; HAYES, JOHN W.; SADOWSKI, PETER L.; JOOSTE, HERMANUS L.; JAFFE, JONATHAN
To: ANTARES PHARMA, INC.
Reel/Frame 059674/0540 →
Continuity (8)
Continuation 16149032 · Oct 1, 2018
Continuation 15238901 · Aug 17, 2016
Continuation 13857859 · Apr 5, 2013
Provisional Application 61783444 · Mar 14, 2013
Provisional Application 61776283 · Mar 11, 2013
Provisional Application 61763395 · Feb 11, 2013
Provisional Application 61621298 · Apr 6, 2012
Related Publication 20210015741A1 · Jan 21, 2021